Your browser doesn't support javascript.
loading
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Brunner, Andrew M; Neuberg, Donna S; Wander, Seth A; Sadrzadeh, Hossein; Ballen, Karen K; Amrein, Philip C; Attar, Eyal; Hobbs, Gabriela S; Chen, Yi-Bin; Perry, Ashley; Connolly, Christine; Joseph, Christelle; Burke, Meghan; Ramos, Aura; Galinsky, Ilene; Yen, Katharine; Yang, Hua; Straley, Kimberly; Agresta, Sam; Adamia, Sophia; Borger, Darrell R; Iafrate, Anthony; Graubert, Timothy A; Stone, Richard M; Fathi, Amir T.
Afiliação
  • Brunner AM; Massachusetts General Hospital, Boston, Massachusetts.
  • Neuberg DS; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wander SA; Massachusetts General Hospital, Boston, Massachusetts.
  • Sadrzadeh H; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ballen KK; Capital Health, Trenton, New Jersey.
  • Amrein PC; Massachusetts General Hospital, Boston, Massachusetts.
  • Attar E; Massachusetts General Hospital, Boston, Massachusetts.
  • Hobbs GS; Massachusetts General Hospital, Boston, Massachusetts.
  • Chen YB; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Perry A; Massachusetts General Hospital, Boston, Massachusetts.
  • Connolly C; Massachusetts General Hospital, Boston, Massachusetts.
  • Joseph C; Massachusetts General Hospital, Boston, Massachusetts.
  • Burke M; Massachusetts General Hospital, Boston, Massachusetts.
  • Ramos A; Massachusetts General Hospital, Boston, Massachusetts.
  • Galinsky I; Massachusetts General Hospital, Boston, Massachusetts.
  • Yen K; Massachusetts General Hospital, Boston, Massachusetts.
  • Yang H; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Straley K; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Agresta S; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Adamia S; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Borger DR; Agios Pharmaceuticals, Cambridge, Massachusetts.
  • Iafrate A; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Graubert TA; Massachusetts General Hospital, Boston, Massachusetts.
  • Stone RM; Massachusetts General Hospital, Boston, Massachusetts.
  • Fathi AT; Massachusetts General Hospital, Boston, Massachusetts.
Cancer ; 125(4): 541-549, 2019 02 15.
Article em En | MEDLINE | ID: mdl-30422308
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Glutaratos / Isocitrato Desidrogenase / Mutação Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Glutaratos / Isocitrato Desidrogenase / Mutação Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2019 Tipo de documento: Article